Page 1

SCIBASE YEAR - END REPORT JANUARY - MARCH 2021 Interim report January 1 - March 31 , 2021 The first quarter in figures Net sales amounted to TSEK 2,562 [ 2,469 ) . The loss after tax amounted to TSEK 8,153 ( 8,936 ) . The loss per share amounted to SEK 0.15 ( 0.54 ) . • The cash flow from current operations was negative in the amount of TSEK 9,473 ( 7,893 ) . The gross margin reached 52.7 % [ 54.0 % ) . Electrode sales volume increased by 14 % and reached 7,496 ( 6,562 ] units , a new quarterly high . Repeat sales of electrodes to existing customers in creased by 18 % . Important events during the quarter Covid - 19 continues to affect sales and the market situation remains difficult to predict going forward , due to ongoing lockdowns and reduced marketing activities . Sales in the company's key market Ger many increased by 3 % [ cleared for currency effects + 9 % ) while overall sales increased by 3 % [ cleared for currency effects + 9 % ) . A further German study evaluating the value of us ing Nevisense on suspected Non - melanoma skin cancer ( NMSC , also known as Keratinocyte cancer ) in normal clinical practice was published . David Melin , SciBase's head of product develop ment , has chosen to leave his position and accept a role at another company . The Company is now look ing for the right profile to take the product / technol ogy platform forward . A nominating committee was appointed . Financial overview THE GROUP Net sales , SEK ths Gross margin , % Equity / Asset ratio , % Net indebtness , multiple Cash equivalents , SEK ths Cashflow from operating activities , SEK ths Earnings per share ( before and after dilution ) , SEK Shareholder's equity per share , SEK Average number of shares , 000 ' Number of shares at closing of period , 000 ' Share price at end of period , SEK Number of sold electrodes , pieces Jan 1 2021 2 562 52,7 % 79,6 % 0,26 31 403 -9473 -0,15 0,70 54 780 54 780 4,78 7496 Average number of employees 18 Definitions and a glossary are provided on page 17 . Mar 31 2020 2 496 54,0 % 64,8 % 0,54 17 970 -7893 -0,38 1,40 16 618 16 618 1,84 6 598 16 Important events after the end of the period SCIBASE SciBase submitted the first US reimbursement ap plication to CMS's Medicare Contractor in Florida , First Coast Service Options ( FCSO ) . The application for Medicare coverage in Florida marks an im portant step in the reimbursement process for Sci Base and is a necessary step towards broader pene tration and usage of the Nevisense test . SciBase received certification under the new Medi cal Device Regulation ( MDR ) . The new Non - Melanoma Skin Cancer ( NMSC ) clini cal application was launched following the comple tion of the MDR certification process . A groundbreaking article by key SciBase collabora tor Professor Cezmi Akdis presenting the " epithelial barrier hypothesis " was published in Nature Reviews Immunology . The article presented the background for the steep increase in allergic and other diseases over the last decades , and how this increase is con nected to degradation in barrier function in the body . A new clinical study from the Swiss Institute of Al lergy and Asthma Research ( SIAF ) was published in the European Journal of Allergy and Clinical Immu nology ( Allergy ) . In the study Nevisense was used to assess the skin barrier of patients with atopic der matitis ( AD ) and could accurately detect signs of barrier degradation in atopic patients , even in visu ally unaffected skin . Nevisense measurements also correlated with relevant biomarkers for atopic der matitis . The notice to attend the AGM 2021 was published as well as the nominating committees supplemen tary proposal to nominate Dr Matt Leavitt for the Board of Directors . The annual report 2020 was published on April 9th Apr 1 2020 - Mar 31 2021 Jan 1 - Dec 31 Rolling - 12 2020 9588 52,2 % 73,3 % 0,36 31 403 -35 441 -0,84 0,76 40 828 54 780 4,78 26 584 17 1 9521 52,5 % 79,1 % 0,26 41427 -33 861 -1,12 1,50 31 287 54 780 4,62 25 686 16 r